D. E. Shaw & Co., Inc. Cti Biopharma Corp Transaction History

D. E. Shaw & Co., Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$5.36 - $7.43 $371,238 - $514,609	-69,261 Reduced 66.7%	34,578 $201,000
Q2 2022 Aug 15, 2022	BUY	$3.55 - $6.27 $368,628 - $651,070	103,839 New	103,839 $620,000
Q3 2020 Nov 16, 2020	SELL	$1.02 - $2.15 $13,471 - $28,395	-13,207 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$0.88 - $1.32 $11,622 - $17,433	13,207 New	13,207 $15,000
Q4 2019 Feb 14, 2020	SELL	$0.72 - $1.64 $15,405 - $35,089	-21,396 Closed	0 $0

Q3 2019 Nov 14, 2019	BUY	$0.64 - $0.92 $6,460 - $9,286	10,094 Added 89.31%	21,396 $18,000
Q3 2018 Nov 14, 2018	BUY	$1.72 - $5.24 $19,439 - $59,222	11,302 New	11,302 $24,000

Ticker CTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,385,000
Market Cap $1.04B
Description
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients w...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.